openPR Logo
Press release

Human Recombinant Insulin Market 2019: Global Trends by Top Players Novo Nordisk A/S, Eli Lilly and Company, Sanofi S.A., Julphar Gulf Pharmaceutical Industries, Biocon Limited, Bioton S.A., Gan & Lee Pharmaceuticals, Ltd., Zhuhai United Laboratories Co

07-09-2019 12:10 PM CET | Health & Medicine

Press release from: Coherent Market Insights (CMI)

Human Recombinant Insulin

Human Recombinant Insulin

Various government and private research organizations are engaged research and development activities for developing advanced treatment in diabetes care to increase the effectiveness of human insulin, reduce diabetes burden, and minimize the risk of diabetes associated disorders such as diabetes-associated blindness, kidney disease, heart attacks, strokes or limb loss. For instance, American Diabetes Association (ADA) invested US$ 807.4 million in more than 4,700 research projects in diabetes research since 1952 till 2017.

According to ADA, 2017 review, ADA invested more than US$ 37.4 million for diabetes research in 2017, and supported 371 diabetes related research projects. The European Foundation for the Study of Diabetes (EFSD): a division of European Association for the Study of Diabetes (EASD), provides funding initiatives in all areas of diabetes research. EFSD aims to accelerates and support research in the field of diabetes to introduce innovative diabetic management portfolio.

Get PDF Brochure of Research Report: https://www.coherentmarketinsights.com/insight/request-pdf/1797

In September 2017, Biocon Limited: an India-based biopharmaceutical firm received funding from Juvenile Diabetes Research Foundation (JDRF) to study oral insulin drug candidate: Tregopil, to evaluate the safety and tolerability in people suffering with type 1 diabetes. The collaboration between Biocon and JDRF is a part of JDRF's Industry Discovery and Development Partnership (IDDP) programme, through which JDRF provides financial support to Biocon to accelerate research in type 1 diabetes management.

According to the International Diabetes Federation (IDF) Atlas 2017, global burden of diabetes is affecting more than 425 million people, among which one-third are older than 65 years of age. Moreover, the number of people with diabetes may rise to 629 million in 2045. Furthermore, 352 million with impaired glucose tolerance are at high risk of developing diabetes. Furthermore, continuous increase in incidence rate of diabetes, owing to unhealthy lifestyle, binge eating, obesity, overweight, physical inactivity, and insulin resistivity among global population is expected to further boost growth of the human recombinant insulin market over the forecast period.

However, high cost of insulin may restrain growth of the market, as patients from low and middle countries are unable to afford it. According to the Pharmaceutical Care Management Association (PCMA) May 2018 report, prices of insulin have increased over 10-fold since 1985 and prices have exhibited significant rise during the last past 10 years (2008 to 2018). According to PCMA, prices for Humulin/Novolin have increased from around US$ 25 per prescription in 1985 to nearly US$ 300 in 2016. Furthermore, prices for long-acting insulins have increased from around US$ 100 per prescription in 2007 to nearly US$ 400 in 2016.

Free Request Sample Copy of This Report: https://www.coherentmarketinsights.com/insight/request-sample/1797

Key players operating in human recombinant insulin market include Novo Nordisk A/S, Eli Lilly and Company, Sanofi S.A., Julphar Gulf Pharmaceutical Industries, Biocon Limited, Bioton S.A., Gan & Lee Pharmaceuticals, Ltd., Zhuhai United Laboratories Co., Ltd., Wanbang Biopharmaceuticals Co., Ltd., and Dongbao Enterprise Group Co., Ltd.

Contact Us:
Mr. Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: sales@coherentmarketinsights.com

About Us:
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Human Recombinant Insulin Market 2019: Global Trends by Top Players Novo Nordisk A/S, Eli Lilly and Company, Sanofi S.A., Julphar Gulf Pharmaceutical Industries, Biocon Limited, Bioton S.A., Gan & Lee Pharmaceuticals, Ltd., Zhuhai United Laboratories Co here

News-ID: 1799873 • Views:

More Releases from Coherent Market Insights (CMI)

Huge Growth in Mobile Imaging Services Market 2023 to see Future Opportunities 2030 | Carestream Health, Accurate Imaging, Inc., Alliance HealthCare Services
Huge Growth in Mobile Imaging Services Market 2023 to see Future Opportunities 2 …
𝗢𝘃𝗲𝗿𝘃𝗶𝗲𝘄: Mobile imaging services are provided by trained professionals who are equipped with state-of-the-art imaging technology that can be transported and set up on location. The images obtained through mobile imaging services are then transmitted electronically to the patient's healthcare provider for analysis and diagnosis. Mobile imaging services are used in a variety of healthcare settings, including hospitals, clinics, nursing homes, and home health agencies. They are particularly useful for imaging patients
Huge Growth in Particle Therapy Market 2023 to see Future Opportunities 2030 | Ion Beam Applications, Provision Healthcare, Mevion Medical Systems
Huge Growth in Particle Therapy Market 2023 to see Future Opportunities 2030 | I …
Coherent Market Insight has published a new research report titled "Particle Therapy Market 2023 analysis by Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges and Investment Opportunities)", size, share, and outlook. This research offers strategic recommendations based on industry experts' consultations on market development, consumer demand, sales patterns, revenue forecasts, gross margins, and regional growth. It focuses on regional developments as well as market growth, pricing, sales patterns, revenue forecasts, and
Digital Mobile X Ray Devices Market 2023 to see Future Opportunities 2030 | Toshiba Corporation, Carestream Health, General Electric Company
Digital Mobile X Ray Devices Market 2023 to see Future Opportunities 2030 | Tosh …
Coherent Market Insight has published a new research report titled "Digital Mobile X Ray Devices Market 2023 analysis by Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges and Investment Opportunities)", size, share, and outlook. This research offers strategic recommendations based on industry experts' consultations on market development, consumer demand, sales patterns, revenue forecasts, gross margins, and regional growth. It focuses on regional developments as well as market growth, pricing, sales patterns,
Huge Growth in Chemiluminescence Imaging Market 2023 to see Future Opportunities 2030 | LI-COR Biosciences, Analytik Jena US, Azure Biosystems, Berthold Technologies GmbH & Co. KG
Huge Growth in Chemiluminescence Imaging Market 2023 to see Future Opportunities …
Coherent Market Insight has published a new research report titled "Chemiluminescence Imaging Market 2023 analysis by Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges and Investment Opportunities)", size, share, and outlook. This research offers strategic recommendations based on industry experts' consultations on market development, consumer demand, sales patterns, revenue forecasts, gross margins, and regional growth. It focuses on regional developments as well as market growth, pricing, sales patterns, revenue forecasts, and

All 5 Releases


More Releases for Diabetes

Reverse Diabetes with Dr. Merritt’s Diabetes Reversal Recipe
[November 26, 2020] – People suffering from diabetes always search for ways to lower blood sugar levels in their bodies. Diabetes treatment available costs you hundreds of dollars yearly and also restricts you to a diabetic diet. That hampers your mental health and well-being. Apart from this, eye problems, kidney failure, amputations are some of the physical problems diabetic patients face. Dr. Marlene Merritt (from the Merritt Wellness Center in
Emerging trends for Diabetes Care Devices Market 2020 astonishing growth by Worl …
The global diabetes care devices market is expected to reach US$ 39,382.3 Mn in 2027 from US$ 23,354.3 Mn in 2018. The market is estimated to grow with a CAGR of 6.1% from 2020-2027. Premium market insights recently published a report titled "Diabetes Care Devices Market Size and Forecast to 2026". The report includes an authentic and accurate research study into the global Diabetes Care Devices market based on a qualitative
Diabetes Treatment
Diabetes Treatment is a important way to help manage the healthy ,easy to use and improve the way of the treatment of blood glucose monitoring system. As living standards improve, an increasing obesity, the Diabetes Treatment has improved peoples living habits, disease control effect, is becoming more and more important. The global Diabetes Treatment market is valued at 43700 million US$ in 2018 and will reach 58000 million US$ by the end
Self-Monitoring Blood Glucose Devices Market Study by Advance Application [Type …
The global self-monitoring blood glucose devices market was valued at $7,768 million in 2017 and is projected to reach $10,828 million by 2025 at a CAGR of 4.2% from 2018 to 2025. Monitoring of blood glucose is an essential step in diabetes management. Blood glucose monitoring devices are predominantly used to monitor a patient’s blood glucose level. Self-monitoring blood glucose (SMBG) devices are easy-to-use and enable people to monitor their
Global Diabetes Industry
Global Diabetes Industry Market Insight Global diabetes market is expected to grow at a CAGR of 7.9% percent for the forecasted period of 2016-2021. The market is segmented on the basis of type of diabetes, drugs class and diabetic devices. Diabetic drugs have the highest market share amongst drugs and devices and are also expected to have the highest growth rate with a CAGR of 9%. Some of the top selling
Diabetes Drugs Market: Increasing Prevalence of Diabetes to Stoke Market Growth
According to the TMR report, the global diabetes drugs market stood at a valuation of US$43.1 bn in 2016 and is likely to be valued at US$58.4 bn by the end of 2025 expanding at a CAGR of 3.6% between 2017 and 2025. Research and Development Pursuits to Introduce Novel Products Stokes Growth The rising per capita income in several parts of world leading to changing lifestyles and adoption of unhealthy food